
handle: 10281/450719
Despite advances in the treatment of several tumors, melanoma remains a cancer with a very poor prognosis. Dacarbazine is considered the standard-of-care for metastatic disease and it has been tested in association with both chemotherapeutic and immunologic drugs. Recent efforts have focused on developing novel targeted therapeutic agents, as more information is available regarding molecular biology of this disease. In this review we discuss the systemic therapeutic options for metastatic melanoma and focus on the new targeted drugs.
Biochemotherapy; Chemotherapy; Immunotherapy; Melanoma; Targeted therapies
Biochemotherapy; Chemotherapy; Immunotherapy; Melanoma; Targeted therapies
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
